Go Deep
Immunome, Inc.
Immunome, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,337 | -7.0 | 3.95 | 0.01 | 1,674.21 |
| Oct 2026 | 19,443 | -6.8 | 3.87 | 0.01 | 1,633.10 |
| Oct 2026 | 19,387 | -7.0 | 3.91 | 0.01 | 1,652.32 |
| Oct 2026 | 19,647 | -6.5 | 3.70 | 0.01 | 1,559.96 |
| Oct 2026 | 19,563 | -6.7 | 3.77 | 0.01 | 1,590.07 |
| Oct 2026 | 19,242 | -7.1 | 4.03 | 0.01 | 1,699.11 |
| Oct 2026 | 19,220 | -7.1 | 4.04 | 0.01 | 1,702.48 |
| Oct 2026 | 19,147 | -7.2 | 4.10 | 0.01 | 1,723.58 |
Immunome, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -73,127,000.0 | -53,839,000.0 | -69,900,000.0 | -57,457,000.0 |
| EPS | -0.7 | -0.5 | — | -0.7 |
Immunome, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 6,941,000.0 | 9,041,000.0 | 14,018,000.0 | 0.0 | — |
| Net Profit | -212,394,000.0 | -292,963,000.0 | -106,806,000.0 | -36,896,000.0 | — |
| EPS | -2.4 | -5.0 | -5.4 | -3.1 | — |
Immunome, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 683,188,000.0 | 240,241,000.0 | 148,540,000.0 | 24,046,000.0 | — |
| Total Liabilities | 48,845,000.0 | 59,076,000.0 | 28,658,000.0 | 7,393,000.0 | — |
| Total Equity | 634,343,000.0 | 181,165,000.0 | 119,882,000.0 | 16,653,000.0 | — |
Owes vs Owns
Immunome, Inc. owed $0.07 for every $1 it owned in Jun 2026, down from $0.31 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.07× | 0.07× | 0.25× | 0.19× | 0.31× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Immunome, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 95.7%Fixed assets (tangible) 2.6%Other assets 1.8%
How it's funded — Dec 2025
Long-term debt 0.6%Other liabilities 6.1%Shareholders' equity 92.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 653.5 | 217.3 | 138.1 | 20.3 |
| Receivables | 0.0 | 0.0 | 0.3 | 0.8 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 17.6 | 14.4 | 3.6 | 1.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 12.1 | 8.5 | 6.5 | 1.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.1 | 0.3 | 0.2 |
| Long-term debt | 3.9 | 4.8 | 1.3 | 0.1 |
| Payables | 3.3 | 14.2 | 3.3 | 2.4 |
| Other liabilities | 41.7 | 40.1 | 23.7 | 4.7 |
| Shareholders' equity | 634.3 | 181.2 | 119.9 | 16.7 |
| Net tangible assets | 634.3 | 181.2 | 119.9 | 16.7 |
Immunome, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -190,919,000.0 | -110,794,000.0 | -7,568,000.0 | -28,690,000.0 | — |
| Investing Activities | 60,803,000.0 | -85,063,000.0 | -30,484,000.0 | -248,000.0 | — |
| Financing Activities | 640,357,000.0 | 240,529,000.0 | 116,408,000.0 | 32,000.0 | — |